Although pharmaceutical prices in Germany remained almost constant in1996 and the number of prescriptions grew only slightly, there was a distinct rise in the value of prescribed drugs, says new data published by the German association of research-based pharmaceutical companies, the VFA.
1996 was distinguished by the introduction of some spectacular therapeutic breakthroughs and the arrival of 36 new products onto the German market, says the VFA. However, also during the year the drug budgets first introduced in 1993 proved to be inadequate for ensuring the long-term provision of high-quality care to all patients, and were thus repealed with new legislation for the reform of the statutory health insurance system.
German Pharma Consumption In 1996, By Volume, By Therapeutic Group % volume sales change from Therapeutic group (mill) 1995 -------------------------------------------------- Respiratory system 319.51 1.1
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze